OBJECTIVE: This analysis estimated the budget impact of the use of D150 and R20 for the treatment of NAFV patients in Italy. Outcomes from observational study demonstrated that D150 and R20 reduced the rate of thromboembolic events. Cardiologia, Ospedale Santa Croce e Carle, Cuneo, Italyĥ Health Publishing & Services Srl, Milan, ItalyīACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation (NVAF). Azienda Ospedaliera San Giovanni Addolorata, Rome, Italyģ Dipartimento Cardiotoracico Azienda Sanitaria Universitaria Integrata di Udine, Udine, ItalyĤ S.C. Maria Grazia Celeste 1, Francesca De Marco 2, Claudio Fresco 3, Giuseppe Musumeci 4, Roberto Ravasio 5ġ UOC Farmacia Clinica, Fondazione PTV Policlinico Tor Vergata, Rome, ItalyĢ UOC Pronto Soccorso e Breve Osservazione. Health economics and therapeutic pathways 2017 18(1): -111īudget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation It binds to Dabigatran and its metabolites and blocks its anticoagulant activity.Farmeconomia. Its action is specific to Dabigatran and not a lot effective towards other anticoagulants. Idarucizumab is a human monoclonal antibody that has a totally high affinity to Dabigatran.

Life-threatening or out of control bleeding.

Your doctor would possibly administer you a 2nd dose of Praxbind Injection if bleeding occurs.

The maximum often occurring side impact associated with anticoagulant use is bleeding, starting from mild to extreme complications.

Your doctor will prescribe this medication while there's an emergency need to inactivate the anticoagulant impact of Dabigatran. It is indicated to reverse the anticoagulant impact of medication referred to as Dabigatran. Praxbind Injection includes the active substance Idarucizumab.

Idarucizumab price